In CRC, a mutant Hydra actinoporin-like-toxin-1 (mHALT-1) immunotoxin was developed to treat KRAS G12V-mutant CRC patients, which showed cytotoxic effects in KRAS-mutant CRC cells [88]. This evidence concerns the gene KRAS and colorectal carcinoma.